AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23571166 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of H1N1 2009 vaccine
Number of subjects: 240
Study 21552482 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet self-help treatment program (22 patients)
Number of subjects: 42
Study 21552482 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 42
Study 19940609 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day laropiprant
Number of subjects: 21
Study 19940609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16728292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored stage‐matched intervention
Number of subjects: 41
Study 16728292 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 41
Study 15324780 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 17
Study 15324780 — intervention group
Group type: COMPARATOR
Intervention: Cold Pressor Test
Number of subjects: 17
Study 15324780 — intervention group
Group type: COMPARATOR
Intervention: Pressure pain tolerance
Number of subjects: 17
Study 11513787 — intervention group
Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 885
Study 11513787 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-gloving system
Number of subjects: 885
Study 11513787 — intervention group
Group type: COMPARATOR
Intervention: Combination gloves
Number of subjects: 885
Study 9096447 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO therapy for 6 months in group I (n = 20)
Number of subjects: 40
Study 9096447 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO therapy and iron supplement in group II (n = 20)
Number of subjects: 40
Study 9096447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical method for estimating iron needs
Number of subjects: 40
Study 8502627 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 800 mg dose of pefloxacin
Number of subjects: 482
Study 8502627 — intervention group
Group type: COMPARATOR
Intervention: 10 days' course of norfloxacin 400 mg bid
Number of subjects: 482
Study 3573825 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion (2 mg/kg over 5 minutes)
Number of subjects: 159
Study 3573825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.5 micrograms/kg as a bolus)
Number of subjects: 159
Study 3573825 — intervention group
Group type: COMPARATOR
Intervention: Basal plasma levels of calcitonin in normal men
Number of subjects: 159
Study 3573825 — intervention group
Group type: COMPARATOR
Intervention: Basal plasma levels of calcitonin in normal women
Number of subjects: 159
Study 28815430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg/day
Number of subjects: 2
Study 28815430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 27659276 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzocaine gel
Number of subjects: 30
Study 27659276 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 24100112 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy (20 mg omeprazole, 1 g amoxicillin, and 500 mg clarithromycin twice daily for 1 week)
Number of subjects: 901
Study 24100112 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 901
Study 24100112 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy
Number of subjects: 901
Study 22662132 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin cream
Number of subjects: 0
Study 22662132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20137365 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐minute formula electro‐acupuncture treatment
Number of subjects: 20
Study 20137365 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study 18441312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 55 IU (68 USP) of ovine hyaluronidase (Vitrase)
Number of subjects: 0
Study 18441312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 75 IU (93 USP) of ovine hyaluronidase (Vitrase)
Number of subjects: 0
Study 18441312 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 15583944 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentiometric immunosensor for adrenal cortical hormones (ACH)
Number of subjects: 0
Study 15583944 — intervention group
Group type: COMPARATOR
Intervention: ELISA method
Number of subjects: 0
Study 12860806 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine 125 brachytherapy
Number of subjects: 842
Study 12860806 — intervention group
Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 842
Study 14655916 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (at least 225 minutes per week)
Number of subjects: 173
Study 14655916 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity stretching
Number of subjects: 173
Study 14655916 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in maximum O2 consumption (>10% increase)
Number of subjects: 173
Study 9521952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin oral suspension (10 mg/kg body weight, three times daily)
Number of subjects: 16
Study 7570860 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive therapy for tuberculosis
Number of subjects: 475
Study 7570860 — intervention group
Group type: COMPARATOR
Intervention: Reasons for not entering the trial
Number of subjects: 475
Study 2575985 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 87
Study 2575985 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol
Number of subjects: 87
Study 2575985 — intervention group
Group type: COMPARATOR
Intervention: both treatments
Number of subjects: 87
Study 1001131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamol/Acetylsalicylic Acid (ASA)
Number of subjects: 96
Study 1001131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (ASA) alone
Number of subjects: 96
Study 1001131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 31706099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg orally twice daily until disease progression, death, or withdrawal
Number of subjects: 225
Study 31706099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 225
Study 30776136 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonists
Number of subjects: 51989
Study 30776136 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonists
Number of subjects: 51989
Study 27871928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily for 6 months
Number of subjects: 42
Study 27871928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27871928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 42
Study 25769003 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin daily
Number of subjects: 1193
Study 25769003 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily
Number of subjects: 1193
Study 25769003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study 25769003 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin daily
Number of subjects: 1193
Study 25769003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose atorvastatin
Number of subjects: 1193
Study 25769003 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treated patients
Number of subjects: 1193
Study 23826798 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care for Preschoolers
Number of subjects: 80
Study 23826798 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study 21605732 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (tailored pictographic 10-year fracture risk estimate, absolute risk reduction with bisphosphonates, side effects, and out-of-pocket cost)
Number of subjects: 100
Study 21605732 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 100
Study 21605732 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard brochure)
Number of subjects: 100
Study 21605732 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 18538536 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad sparing approach
Number of subjects: 59
Study 18538536 — intervention group
Group type: COMPARATOR
Intervention: Standard median parapatellar incision
Number of subjects: 59
Study 18538536 — intervention group
Group type: COMPARATOR
Intervention: Mini mid-vastus approach
Number of subjects: 59
Study 17083766 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and prednisolone
Number of subjects: 0
Study 15305885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid with heparin
Number of subjects: 9
Study 15305885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid alone
Number of subjects: 9
Study 15305885 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 9
Study 10708327 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based drug prevention, education, and treatment projects providing case management and referral to services or day treatment
Number of subjects: 370
Study 10708327 — intervention group
Group type: COMPARATOR
Intervention: Alternative or no intervention
Number of subjects: 370
Study 9081694 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate dietary intervention (NCEP step II diet)
Number of subjects: 409
Study 9081694 — intervention group
Group type: COMPARATOR
Intervention: Delayed dietary intervention (control group)
Number of subjects: 409
Study 8471129 — intervention group
Group type: EXPERIMENTAL
Intervention: MDE (140 mg)
Number of subjects: 14
Study 8471129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31467033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 215
Study 31467033 — intervention group
Group type: COMPARATOR
Intervention: IFN β‐1a
Number of subjects: 215
Study 29609644 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Psychological Care (EPC)
Number of subjects: 29
Study 29609644 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 29
Study 27500639 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime-recombinant adenovirus 5 (rAd5) boost HIV vaccine
Number of subjects: 0
Study 24377454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio nuts (20% energy daily)
Number of subjects: 60
Study 22592096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-1.0 µg calcitriol and 1200 IU (30 µg) cholecalciferol
Number of subjects: 61
Study 22592096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU cholecalciferol
Number of subjects: 61
Study 22592096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 22592096 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in 1,25-dihydroxyvitamin D
Number of subjects: 61
Study 22592096 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in parathyroid hormone
Number of subjects: 61
Study 22592096 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 61
Study 20642344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular sarcoidosis group (N = 60)
Number of subjects: 95
Study 20642344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular sarcoidosis group with annual household income < $50,000
Number of subjects: 95
Study 20642344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular sarcoidosis group with visual acuity 20/100 or worse
Number of subjects: 95
Study 20642344 — intervention group
Group type: COMPARATOR
Intervention: Non-ocular sarcoidosis group (N = 35)
Number of subjects: 95
Study 18678155 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Shuigou (GV 26) plus western medicine
Number of subjects: 276
Study 18678155 — intervention group
Group type: COMPARATOR
Intervention: Simple western medicine
Number of subjects: 276
Study 15779698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diets
Number of subjects: 0
Study 15779698 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diets
Number of subjects: 0
Study 12905485 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited disease
Number of subjects: 180
Study 12905485 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe disease
Number of subjects: 180
Study 10367592 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg, n = 11)
Number of subjects: 22
Study 10367592 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors (n = 11)
Number of subjects: 22
Study 9087091 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV immune globulin (RSV-IG)
Number of subjects: 0
Study 1677361 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.300 mg, orally) and Pyridostigmine (120 mg, orally)
Number of subjects: 8
Study 1677361 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg, im)
Number of subjects: 8
Study 1677361 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg, im) and Clonidine (0.300 mg, orally)
Number of subjects: 8
Study 1677361 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (30 mg, orally)
Number of subjects: 8
Study 1677361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6342357 — intervention group
Group type: EXPERIMENTAL
Intervention: Coingestion of 50 g fat (butter) with 50 g carbohydrate (potato)
Number of subjects: 8
Study 6342357 — intervention group
Group type: EXPERIMENTAL
Intervention: Coingestion of 50 g fat (butter) with 50 g protein (low fat veal)
Number of subjects: 8
Study 31237182 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) after four treatments
Number of subjects: 69
Study 31237182 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study 31237182 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely depressed patients
Number of subjects: 69
Study 29987144 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of Naphthoquine-Azithromycin (NQAZ)
Number of subjects: 480
Study 29987144 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of Naphthoquine-Azithromycin (NQAZ)
Number of subjects: 480
Study 29987144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 26872898 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze dressings soaked in normal saline at 42°C (experimental)
Number of subjects: 10
Study 26872898 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressings soaked in normal saline at room temperature (control)
Number of subjects: 10
Study 24414439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 100
Study 24414439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid fixation
Number of subjects: 100
Study 22365709 — intervention group
Group type: EXPERIMENTAL
Intervention: Definity (10 μL/kg) as a slow bolus over 30 to 60 sec
Number of subjects: 32
Study 20202514 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (10 to 40 mg)
Number of subjects: 247
Study 20202514 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 247
Study 17210069 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP infusions with usual palliative care and dietetic advice
Number of subjects: 100
Study 17210069 — intervention group
Group type: COMPARATOR
Intervention: Usual palliative care and dietetic advice without ATP
Number of subjects: 100
Study 15757771 — intervention group
Group type: EXPERIMENTAL
Intervention: Static splintage
Number of subjects: 42
Study 15757771 — intervention group
Group type: COMPARATOR
Intervention: Interphalangeal joint mobilization with metacarpophalangeal joint immobilization
Number of subjects: 42
Study 15757771 — intervention group
Group type: COMPARATOR
Intervention: Norwich regime
Number of subjects: 42
Study 11925464 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole almonds (WA)
Number of subjects: 22
Study 11925464 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond oil (AO)
Number of subjects: 22
Study 9583926 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa and a dopa decarboxylase inhibitor in combination with selegiline (arm 2)
Number of subjects: 624
Study 9583926 — intervention group
Group type: COMPARATOR
Intervention: Levodopa and a dopa carboxylase inhibitor (arm 1)
Number of subjects: 624
Study 8563903 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-elemental diet
Number of subjects: 0
Study 8563903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Number of subjects: 0
Study 8563903 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0
Study 2696670 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravitreal 5-FU
Number of subjects: 51
Study 2696670 — intervention group
Group type: COMPARATOR
Intervention: Control (no 5-FU)
Number of subjects: 51
Study 797205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 119
Study 797205 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 119
Study 797205 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 119
Study 30782281 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine-enriched nutritional support
Number of subjects: 225
Study 30782281 — intervention group
Group type: COMPARATOR
Intervention: Control group (nutritional support without alanyl-glutamine)
Number of subjects: 225
Study 30782281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 225
Study 27549309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU cholecalciferol/day
Number of subjects: 203
Study 27549309 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 203
Study 27803047 — intervention group
Group type: COMPARATOR
Intervention: diet
Number of subjects: 439
Study 27803047 — intervention group
Group type: COMPARATOR
Intervention: exercise
Number of subjects: 439
Study 27803047 — intervention group
Group type: COMPARATOR
Intervention: diet + exercise
Number of subjects: 439
Study 27803047 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 439
Study 25136550 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week lifestyle intervention
Number of subjects: 60
Study 25136550 — intervention group
Group type: COMPARATOR
Intervention: Advice-only control group
Number of subjects: 60
Study 22440491 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 100
Study 22440491 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban 25 μg/kg bolus
Number of subjects: 100
Study 22440491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban bolus with post-bolus 2-h infusion
Number of subjects: 100
Study 22440491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban bolus with concomitant prasugrel
Number of subjects: 100
Study 21053455 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and beta2 agonists for eight weeks (Group A)
Number of subjects: 55
Study 21053455 — intervention group
Group type: COMPARATOR
Intervention: Oral beta2 agonists only for eight weeks (Group B)
Number of subjects: 55
Study 17692642 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (40 microg/kg)
Number of subjects: 20
Study 17692642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 15881482 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 51
Study 15881482 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (10 mg)
Number of subjects: 51
Study 12056584 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 80
Study 10421037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (group P, 316 patients)
Number of subjects: 616
Study 10421037 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin-oxacillin combination (group C, 300 patients)
Number of subjects: 616
Study 10421037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (P and C)
Number of subjects: 616
Study 7499684 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ppb NO2 for 6 hours
Number of subjects: 8
Study 7499684 — intervention group
Group type: COMPARATOR
Intervention: Air for 6 hours
Number of subjects: 8
Study 2205964 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg on the first day, then 50 mg daily)
Number of subjects: 0
Study 2205964 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 6444678 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical program of tretinoin, benzoyl peroxide, and water avoidance
Number of subjects: 118
Study 6444678 — intervention group
Group type: COMPARATOR
Intervention: Systemic tetracycline therapy with abradant cleansers
Number of subjects: 118
Study 6444678 — intervention group
Group type: COMPARATOR
Intervention: Systemic tetracycline therapy with topically applied tretinoin
Number of subjects: 118
Study 6444678 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical program
Number of subjects: 118
Study 31977842 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5.0 mg/d on days 3-5 of menstrual cycle for 5 days)
Number of subjects: 96
Study 31977842 — intervention group
Group type: COMPARATOR
Intervention: Human Menopausal Gonadotropin (75 U/d intramuscular injection starting from day 3 of menstrual cycle for 5 days)
Number of subjects: 96
Study 31977842 — intervention group
Group type: COMPARATOR
Intervention: Human Menopausal Gonadotropin
Number of subjects: 96
Study 31977842 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 96
Study 31614331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-set configuration (20-s rest every 2 repetitions)
Number of subjects: 26
Study 31614331 — intervention group
Group type: COMPARATOR
Intervention: Traditional-set configuration (no interrepetition rest)
Number of subjects: 26
Study 27683073 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic bone substitute (MBS) - Bioresorb®
Number of subjects: 60